


Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy.

Complete response to avelumab and IL-15 superagonist N-803 with Abraxane in Merkel cell carcinoma: a case study

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
